580 results about "Crystalline particle" patented technology

In a process for producing an oriented inorganic crystalline film, a non-monocrystalline film containing inorganic crystalline particles is formed on a substrate by a liquid phase technique using a raw-material solution which contains a raw material and an organic solvent, where the inorganic crystalline particles have a layered crystal structure and are contained in the raw material. Then, the non-monocrystalline film is crystallized by heating the non-monocrystalline film to a temperature equal to or higher than the crystallization temperature of the non-monocrystalline film so that part of the inorganic crystalline particles act as crystal nuclei.

The invention discloses a long- cycle and high-safety power lithium ion battery positive electrode material and a preparation method thereof. The positive electrode material can be shown as a general formula LiNi<(1-a-b-c)>CoMnM<c>O2.xLiM<1>O<y>, wherein a is greater than 0 and less than 1, b is greater than 0 and less than 1, a+b+c is greater than 0 and less tan 1, x is greater than 0 and less than 0.1, and y is greater than 1 and less than 5; LiNi<(1-a-b-c)>CoMnM<c>O2 is a primary active crystalline particle of the positive electrode material, and is a lithiated composite oxide composed of nickel cobalt manganese and doping element M; and the LiM<1>O<y> is a coating layer coating crystal boundary of the primary active crystalline particle and surface of a polycrystalline secondary particle. The positive electrode material provided by the invention has high stability of crystalline main body, surface and crystal boundary, has good compatibility with electrolyte and is not liable to generate side reaction. The material provided by the invention is used for batteries, has long cycle life, high over-charging resisting capability, good high temperature and high voltage performance and high integral safety, and is particularly suitable for power batteries.

Disclosed is a thin film transistor which includes, over a substrate having an insulating surface, a gate insulating layer covering a gate electrode; a semiconductor layer which functions as a channel formation region; and a semiconductor layer including an impurity element imparting one conductivity type. The semiconductor layer exists in a state that a plurality of crystalline particles is dispersed in an amorphous silicon and that the crystalline particles have an inverted conical or inverted pyramidal shape. The crystalline particles grow approximately radially in a direction in which the semiconductor layer is deposited. Vertexes of the inverted conical or inverted pyramidal crystal particles are located apart from an interface between the gate insulating layer and the semiconductor layer.

An aluminum alloy forged material for automotive vehicles comprises 0.6ˆ¼1.2 mass% of Mg, 0.7ˆ¼1.5 mass% of Si, 0.1ˆ¼0.5 mass% of Fe, 0.01ˆ¼0.1 mass% of Ti, 0.3ˆ¼1.0 mass% of Mn, at least one of 0.1ˆ¼0.4 mass% of Cr and 0.05ˆ¼0.2 mass% of Zr, a restricted amount of Cu that is less than or equal to 0.1 mass%, a restricted amount of Zn that is less than or equal to 0.05 mass %, a restricted amount of H that is less than or equal to 0.25 ml in 100g A1 and a remainder of A1 and inevitably contained impurities, and the material includes precipitated crystalline particles among which the largest one has a maximum equivalent circle diameter equal to or less than 8 µm and an area ratio of the precipitated crystalline particles is equal to or less than 3.6%.

The present invention relates to novel ramipril crystalline particles with improved stability and bioavailability. More particularly, the present invention is directed to individually coated, single ramipril crystalline particles for pharmaceutical and biopharmaceutical applications in oral therapies that are stabilized against decomposition into degradation products, namely, ramipril-DKP and ramipril-diacid, during formulation and storage conditions. The present invention also relates to stabilized ramipril pharmaceutical compositions, novel anhydrous pharmaceutical grade ramipril powders, methods for improving ramipril bioavailability, and methods of manufacture and stabilization of ramipril formulations. The novel, anhydrous pharmaceutical grade ramipril powders and ramipril compositions and dosage forms formed therewith are useful in the treatment of cardiovascular disorders and have the advantage that they provide greater stability against decomposition into ramipril-DKPs and ramipril-diacids under formulation and storage conditions. In addition, they maintain consistent label ramipril potency over extended shelf-life and provide reduced in vivo variability in the bioavailability of ramipril among subjects when administered orally.